Want to see FBRX full AI Analyst Report?
FBRX Stock Chart & Stats
$33.92
-$0.92(-4.43%)
At close: 4:00 PM EST
$33.92
-$0.92(-4.43%)
Day’s Range― - ―
52-Week Range$9.10 - $45.36
Previous CloseN/A
Volume20.10K
Average Volume (3M)97.46K
Market Cap
$751.57M
Enterprise Value$186.03M
Total Cash (Recent Filing)$58.22M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.81
Next Earnings
Aug 17, 2026EPS Estimate
-1.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.58
Shares Outstanding20,478,817
10 Day Avg. Volume83,173
30 Day Avg. Volume97,456
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)65.81
Price to Sales (P/S)0.00
P/FCF Ratio-78.70
Enterprise Value/Market Cap0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-31.00K
Enterprise Value/Ebitda-2.50
Forecast
1Y Price Target
$67.00Price Target Upside97.52% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-4.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Positive Clinical Data (FB102)Durable clinical efficacy and favorable safety in a randomized Phase 1b (29.6% mean improvement vs placebo) materially de-risks FB102’s program, strengthens the autoimmune pipeline, and improves partner and investor optionality for funding or collaboration over the next 2–6 months.
Debt-free Balance SheetA zero-debt capital structure reduces fixed financial obligations and interest risk, giving management flexibility to fund clinical programs via equity or partnerships and preserving runway compared to peers with leverage; this is a durable reduction in default risk.
Governance And Board ContinuityRe-election of directors and ratification of the auditor signal stable governance and continuity in oversight and incentives, which supports consistent clinical development strategy, smoother decision-making on financings or collaborations, and long-term execution.
Bears Say
No Revenue GenerationAbsence of operating revenue means the company is reliant on external capital to fund operations; sustained large losses reduce shareholder equity and increase dilution risk from future financings, creating structural funding pressure over the next several quarters.
High Cash BurnConsistent negative operating and free cash flow consumes cash runway, forcing management to pursue equity raises or partnerships. This persistent burn undermines strategic optionality and can delay or constrain clinical programs if new funding terms are unfavorable.
Declining Equity And ProfitabilityWidening losses and declining shareholder equity reflect deterioration in financial resilience; negative returns on equity and shrinking assets reduce the company's ability to absorb setbacks or fund expansion internally, raising long-term execution risk.
Forte Biosciences News
FBRX FAQ
What was Forte Biosciences Inc.’s price range in the past 12 months?
Forte Biosciences Inc. lowest stock price was $9.10 and its highest was $45.36 in the past 12 months.
What is Forte Biosciences Inc.’s market cap?
Forte Biosciences Inc.’s market cap is $751.57M.
When is Forte Biosciences Inc.’s upcoming earnings report date?
Forte Biosciences Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 37 days.
How were Forte Biosciences Inc.’s earnings last quarter?
Forte Biosciences Inc. released its earnings results on May 11, 2026. The company reported -$1.24 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.24.
Is Forte Biosciences Inc. overvalued?
According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued.
Does Forte Biosciences Inc. pay dividends?
Forte Biosciences Inc. does not currently pay dividends.
What is Forte Biosciences Inc.’s EPS estimate?
Forte Biosciences Inc.’s EPS estimate is -1.03.
How many shares outstanding does Forte Biosciences Inc. have?
Forte Biosciences Inc. has 20,478,817 shares outstanding.
What happened to Forte Biosciences Inc.’s price movement after its last earnings report?
Forte Biosciences Inc. reported an EPS of -$1.24 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 8.243%.
Which hedge fund is a major shareholder of Forte Biosciences Inc.?
Currently, no hedge funds are holding shares in FBRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Forte Biosciences Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$67.00 (97.52% Upside)
$67.00 (97.52% Upside)
Blogger Sentiment
Bullish
FBRX Sentiment 75%
Sector Average 69%
Sector Average 69%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
157.71%
12-Months-Change
Fundamentals
Return on Equity
-106.16%
Trailing 12-Months
Asset Growth
41.64%
Trailing 12-Months
Company Description
Forte Biosciences Inc.
Forte Biosciences, Inc. is a U.S.-based biopharmaceutical company currently in its clinical development phase. The firm's key initiative involves advancing the FB-102 program, which is designed to tackle a variety of autoimmune conditions, notably vitiligo and alopecia areata. Their main offices are situated in Dallas, Texas.
FBRX Stock 12 Month Forecast
Average Price Target
$67.00
▲(97.52% Upside)
Technical Analysis
Coherus Biosciences
―
SELLAS Life Sciences Group
―
Protalix
―
Protara Therapeutics
―
Innate Pharma
―
Ownership Overview
1.83% Insiders
20.69% Mutual Funds
35.53% Other Institutional Investors
33.45% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---